Adello Biologics 

Headquartered in Piscataway, NJ, Adello Biologics is a clinical-stage developer and manufacturer of biosimilar therapeutics in oncology and immunology. Adello’s two lead products, biosimilar versions of Neupogen (filgrastim) and Neulasta (pegfilgrastim), are both expected to be filed with the FDA by the end of this year. Led by Chintu Patel and driven by a team of highly skilled industry veterans, Adello is advancing a pipeline of complex proteins and monoclonal antibodies with the aim of providing high-quality, affordable biosimilars to patients worldwide.